{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:48:32Z","timestamp":1791330512595,"version":"4.3.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T00:00:00Z","timestamp":1473897600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s11910-016-0695-9","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T02:52:16Z","timestamp":1473907936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Prevention of Epilepsy: Issues and Innovations"],"prefix":"10.1007","volume":"16","author":[{"given":"Dieter","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Sillanp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"695_CR1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1124\/pr.110.003046","volume":"62","author":"W L\u00f6scher","year":"2010","unstructured":"L\u00f6scher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev. 2010;62:668\u2013700.","journal-title":"Pharmacol Rev"},{"key":"695_CR2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/archneurol.2009.10","volume":"66","author":"MA Dichter","year":"2009","unstructured":"Dichter MA. Emerging concepts in the pathogenesis of epilepsy and epileptogenesis. Arch Neurol. 2009;66:443\u20137.","journal-title":"Arch Neurol"},{"issue":"Pt A","key":"695_CR3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.yebeh.2015.08.037","volume":"52","author":"W L\u00f6scher","year":"2015","unstructured":"L\u00f6scher W, Hirsch LJ, Schmidt D. The enigma of the latent period in the development of symptomatic acquired epilepsy\u2014traditional view versus new concepts. Epilepsy Behav. 2015;52(Pt A):78\u201392. An important article about the latent period as a window of therapeutic opportunity for preventions trial in epilepsy.","journal-title":"Epilepsy Behav"},{"key":"695_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuropharm.2012.01.022","volume":"69","author":"RS Sloviter","year":"2012","unstructured":"Sloviter RS, Bumanglag AV. Defining \u201cepileptogenesis\u201d and identifying \u201cantiepileptogenic targets\u201d in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology. 2012;69:3\u201315.","journal-title":"Neuropharmacology"},{"issue":"Suppl 2","key":"695_CR5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2008.02005.x","volume":"50","author":"NR Temkin","year":"2009","unstructured":"Temkin NR. Preventing and treating posttraumatic seizures: the human experience. Epilepsia. 2009;50 Suppl 2:10\u20133.","journal-title":"Epilepsia"},{"key":"695_CR6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrd4126","volume":"12","author":"W L\u00f6scher","year":"2013","unstructured":"L\u00f6scher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for antiepileptic drug discovery and development. Nat Rev Drug Discov. 2013;12:757\u201376.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"695_CR7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archneur.1995.00540280045017","volume":"52","author":"FE Dreifuss","year":"1995","unstructured":"Dreifuss FE. Prevention as it pertains to epilepsy. Arch Neurol. 1995;52(4):363\u20136.","journal-title":"Arch Neurol"},{"issue":"4","key":"695_CR8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2015.4515","volume":"73","author":"M Sillanp\u00e4\u00e4","year":"2016","unstructured":"Sillanp\u00e4\u00e4 M, Gissler M, Schmidt D. Efforts in epilepsy prevention in the last 40 years: lessons from a large nationwide study. JAMA Neurol. 2016;73(4):390\u20135. An important article showing that we failed to prevent epilepsy in people below age 65 and a massive increase in epilepsy in the elderly.","journal-title":"JAMA Neurol"},{"issue":"4","key":"695_CR9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaneurol.2015.4780","volume":"73","author":"M Agostini","year":"2016","unstructured":"Agostini M. The prevention of epilepsy. JAMA Neurol. 2016;73(4):375\u2013610.","journal-title":"JAMA Neurol"},{"key":"695_CR10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eplepsyres.2005.09.015","volume":"68","author":"ST Herman","year":"2006","unstructured":"Herman ST. Clinical trials for prevention of epileptogenesis. Epilepsy Res. 2006;68:35\u20138.","journal-title":"Epilepsy Res"},{"issue":"5-6","key":"695_CR11","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.neuropharm.2011.07.038","volume":"61","author":"RS Sloviter","year":"2011","unstructured":"Sloviter RS. Progress on the issue of excitotoxic injury modification vs. real neuroprotection; implications for post-traumatic epilepsy. Neuropharmacology. 2011;61(5-6):1048\u201350.","journal-title":"Neuropharmacology"},{"issue":"3","key":"695_CR12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neulet.2011.03.010","volume":"497","author":"R Mani","year":"2011","unstructured":"Mani R, Pollard J, Dichter MA. Human clinical trials in antiepileptogenesis. Neurosci Lett. 2011;497(3):251\u20136.","journal-title":"Neurosci Lett"},{"key":"695_CR13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1684\/epd.2012.0512","volume":"14","author":"D Schmidt","year":"2012","unstructured":"Schmidt D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Epilept Disord. 2012;14:105\u201313.","journal-title":"Epilept Disord"},{"issue":"2","key":"695_CR14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13311-014-0257-2","volume":"11","author":"A Pitk\u00e4nen","year":"2014","unstructured":"Pitk\u00e4nen A, Engel Jr J. Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics. 2014;11(2):231\u201341.","journal-title":"Neurotherapeutics"},{"issue":"8","key":"695_CR15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1474-4422(16)00112-5","volume":"15","author":"A Pitk\u00e4nen","year":"2016","unstructured":"Pitk\u00e4nen A, L\u00f6scher W, Vezzani A, et al. Advances in the development of biomarkers for epilepsy. Lancet Neurol. 2016;15(8):843\u201356. A good overview showing where how we stand in the discovery of biomarkers for epilepsy development.","journal-title":"Lancet Neurol"},{"issue":"11","key":"695_CR16","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/epi.13201","volume":"56","author":"M Baulac","year":"2015","unstructured":"Baulac M, de Boer H, Elger C, et al. Epilepsy priorities in Europe: a report of the ILAE-IBE Epilepsy Advocacy Europe Task Force. Epilepsia. 2015;56(11):1687\u201395.","journal-title":"Epilepsia"},{"key":"695_CR17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/9781118936979.ch5","volume-title":"Treatment of epilepsy","author":"D Schmidt","year":"2015","unstructured":"Schmidt D. Chapter 5 antiepileptic drug development. In: Shorvon SD, Perucca E, Engel Jr J, editors. Treatment of epilepsy. 4th ed. Newark: Wiley-Blackwell; 2015. p. 61\u201374.","edition":"4"},{"issue":"2","key":"695_CR18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s13311-013-0252-z","volume":"11","author":"D Schmidt","year":"2014","unstructured":"Schmidt D, Friedman D, Dichter MA. Anti-epileptogenic clinical trial designs in epilepsy: issues and options. Neurotherapeutics. 2014;11(2):401\u201311.","journal-title":"Neurotherapeutics"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-016-0695-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-016-0695-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-016-0695-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T01:25:59Z","timestamp":1601083559000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-016-0695-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1007\/s11910-016-0695-9","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,15]]},"article-number":"95"}}